Real-Life Effectiveness and Safety of Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: A Single-Center 16-Week Study

INTRODUCTION: The treatment of severe atopic dermatitis (AD) includes cyclosporine and recently approved biologics and small molecules. Among these, upadacitinib is a selective inhibitor of Janus kinase 1, approved for the treatment of severe AD in adolescents/adults. Upadacitinib has shown efficacy...

Descripción completa

Detalles Bibliográficos
Autores principales: Gargiulo, Luigi, Ibba, Luciano, Cortese, Andrea, Avagliano, Jessica, Valenti, Mario, Costanzo, Antonio, Narcisi, Alessandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9827011/
https://www.ncbi.nlm.nih.gov/pubmed/36617589
http://dx.doi.org/10.1007/s13555-022-00882-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9827011/
https://www.ncbi.nlm.nih.gov/pubmed/36617589
http://dx.doi.org/10.1007/s13555-022-00882-z

Ejemplares similares